A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma. [electronic resource]
Producer: 20170602Description: 576-582 p. digitalISSN:- 1097-0142
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Biomarkers, Tumor -- genetics
- Carcinoma, Renal Cell -- drug therapy
- DNA-Binding Proteins
- Disease-Free Survival
- Drug-Related Side Effects and Adverse Reactions -- pathology
- Female
- Humans
- Kaplan-Meier Estimate
- Lysophospholipids -- antagonists & inhibitors
- Male
- Middle Aged
- Neoplasm Metastasis
- Nuclear Proteins -- genetics
- Sphingosine -- analogs & derivatives
- Transcription Factors -- genetics
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Von Hippel-Lindau Tumor Suppressor Protein -- genetics
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article
There are no comments on this title.
Log in to your account to post a comment.